List of Biotech, Pharmaceutical & Life Sciences companies in Nevada - 18

We are a clinical stage diagnostics company committed to developing and commercializing novel products for the treatment and management of all cancers.

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

Algae Systems is a full service algae to energy technology development and commercialization firm focusing on autotrophic algal solutions for the production of carbon negative high-BTU liquid fuels, water treatment and other high value products. Algae Systems was founded by a group of renewable energy veterans, NASA engineers, business executive consultants and IT experts. We are developing low-tech, highly scalable carbon-negative fuel production infrastructure that simultaneously treats wastewater and provides other services to industralized and developing economies.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease, as well as Phase 2 clinical trial for the treatment of Parkinson’s disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Our Mission: Urgently impact climate change, at scale, by harnessing the power of Asparagopsis seaweed to reduce methane from cows. This is because we believe: * Climate change is real. Humanity is running out of time to act. Agriculture/methane is a significant contributor to climate change. * Nature can inspire and technology can deliver a meaningful difference. Seaweed is an unrealized resource that nature has provided to reduce methane in cows. * We are realists about convincing the world to do things differently. We want to make change as easy as possible. * We are certain that we can make a difference by bringing individuals, communities, governments and industry together. The company's bold vision is for Zero Methane Agriculture by bending the climate curve. because cutting methane will significantly slow short-term global warming. CH4's urgent initiative is to cut methane emissions from livestock by making available to the world sustainable, globally-scaled products containing a unique seaweed. This special seaweed, Asparagopsis, has over 10 years of research behind it and has shown effects of 60-90% reduction in methane emissions from both dairy and beef cattle and sheep. As we, at CH4 Global, work to make Asparagopsis products real, we are committed to doing this in a way that makes it easy for farmers to adopt and that will benefit communities where we aqua-farm. We are collaborating with local communities to ensure that all can benefit from our work. Our Management Team and Advisory Board come with significant research, development, marketing, large-scale production, distribution and investment experience in major global companies. We are based in USA, New Zealand and Australia.

CV Sciences produces both pharmaceuticals and consumer products. ThePharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider’s offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician’s recommendations.

Diagnostics

Hamilton Company is a global enterprise with headquarters in Reno, Nevada; Franklin, Massachusetts; and Bonaduz, Switzerland and subsidiary offices throughout the world. We are an industry leader in the design and manufacture of liquid handling, process analytics, robotics and automated storage solutions. For more than 60 years, Hamilton has been meeting customer needs with a combination of quality materials and skilled workmanship that ensures the highest level of performance. Hamilton's continued commitment to precision and quality has earned the company global ISO 9001 Certification. Founded on the technology of analytical microliter and gastight syringes, Hamilton has a broad offering of laboratory products including manual and semi-automated precision fluid measuring instruments, chromatography products, process sensors, laboratory electrodes, pipettes and more. Top innovations from these lines include Arc™ pH, DO and conductivity intelligent sensors, the BioLevitator™ 3D cell culture system, Microlab® 600 diluters/dispensers and the Microlab 300 guided pipetting system. The leader in liquid handling technology, Hamilton Robotics is recognized for advancing life science and biotechnology industries with products that offer reliability, performance and flexibility. Hamilton is the industry leader in design and manufacturing, with patented technologies such as Compression-induced O-Ring Expansion CO-RE™, Total Aspiration and Dispensing Monitoring TADM™ and Anti-Droplet Control ADC™. Hamilton's platforms include VANTAGE Liquid Handling System™, Microlab STAR™ and Microlab NIMBUS®. Hamilton Storage offers comprehensive ultra-low temperature automated sample management systems for microtube and microplate storage. Hamilton's line of biobanking and compound storage solutions and consumables is designed for a broad array of life science processes. Products include BiOS™, SAM™ and ASM™, designed for sample integrity, flexibility and reliability.

Heligenics is a life sciences company that has developed proprietary technology, which shows the impact of genetic mutations to revolutionize genetic testing and drug development for major diseases. We are the first company to develop High Content Screening for Biologic Drugs, previously the mainstay for the development of small compound drugs. As the effect of most mutations on gene function is largely unknown, Heligenics comprehensively measures the functional significance of mutations in the human genome through a massively parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do if at all. For cancer diagnostics companies, our functional data enables improved genetic test interpretation, and for pharmaceutical companies, we empower the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically stratified clinical trial. Explore more! Email: mschiller@heligenics.com Website: Heligenics.com LinkedIn: linkedin.com/company/heligenics-inc/ Twitter: twitter.com/heligenics

Kleiner Device Labs - Advancing Minimally Invasive Spinal Surgery™ During 25 years of active spinal surgical practice and over 6,000 surgeries, Dr. Jeffrey Kleiner became increasingly aware that instrument design and quality played a significant role in the clinical outcome of spinal surgery. He recognized key gaps in the instrumentation available to spinal surgeons and this led him to develop a series of innovative solutions. In 2013, Dr. Kleiner established Kleiner Device Labs to build and sell innovative spinal surgical products. These novel and advanced tools deliver improvements in efficiency and safety for patients and enable surgeons to perform more effective and less complicated fusion surgery. Kleiner Device Lab's first product, a Bi-Directional Graft Funnel (KG™1), works with any flowable biologic graft material, provides a more efficient and safer delivery vehicle for bone graft extenders, facilitates grafting in front of or alongside all types of interbody cages and can eliminate or reduce surgeon dependency on BMP. Building on the underlying philosophy behind the KG™1, Kleiner Device Labs developed the KG™2 Surge™ Flow-Thru Interbody Implant in 2021. No other device integrates implant positioning and graft delivery like the KG™2 Surge™. The system not only maximizes successful outcomes for patients (while simplifying the procedure for surgeons) but reduces costs for healthcare providers and insurers as well. Kleiner Device Labs has a broad patent portfolio and a runway of innovative minimally invasive spinal surgical products. These strategies are equally effective in open theater surgical technique as well.

Provide protein expression services across multiple platforms (E. coli, baculovirus, mammalian cell),mtibiooffers fully customizable protein purification services that go above and beyond industry standard offerings such as our proprietary ULE (ultra-low endotoxin) purification services (< 0.005 EU/ml) and ULE non-detergent endotoxin removal (< 0.1 EU/mg) as well as a host of custom services that add value for clients in both upstream and downstream applications.

Nevada's land-grant university founded in 1874, the University of Nevada, Reno has an enrollment of more than 21,000 students. The University is home to one of the country's largest study-abroad programs and the state's medical school, and offers outreach and education programs in all Nevada counties. Specialties earth sciences, engineering, seismology, geology, journalism, biochemistry, chemistry, physics, gaming studies, basque studies, business administration

RosVivo Therapeutics is a biotechnology company that develops microRNA-based therapeutics for type 2 diabetes, obesity, and fatty liver disease. They have signed a Material Transfer Agreement for first-in-class diabetes treatment with Eli Lilly and Company.

Rxight, developed by MD Labs, is a pharmacogenetic program that helps patients get the right medication at the right dose, the first time, based on their genetic profile. Importantly, Rxight also helps patients avoid medications that are ineffective or could cause dangerous side effects or adverse drug reactions. The MD Labs Rxight team was invited to the White House to present this novel Precision Medicine program to the Office of Science and Technology Policy. Go to our website to learn more. MD Labs was founded in 2011 with the goal to specialize in prescription monitoring toxicology and serve physicians across the United States. Our founders, Matthew Rutledge and Denis Grizelj started the company with the goal of creating a more provider-friendly testing service that prides itself on delivering prompt, accurate, reliable and easy to understand results.

A diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio®, we see things differently. We develop and commercialize innovative medicines and life changing products for the patients that need them most.

SFI Health are global leaders in developing & delivering human microbiome and cognitive natural health solutions that enable people to make informed health choices confidently. We believe we have the responsibility to bring proven natural health solutions to people’s healthcare needs. Our guiding principle is that our people act with integrity, courage and passion to: • Make a difference • Progress human quality of life • Act on learnings • Perform to promises made • Promote diversity

"Zhittya (meaning Life in Ukrainian) is a biotechnology company based in Las Vegas, Nevada. Zhittya is seeking to commercialize human FGF-1, a naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have been working to bring this drug to market. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. There are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues, and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.